Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 28;19(15):9265.
doi: 10.3390/ijerph19159265.

Needs of Lung Cancer Patients Receiving Immunotherapy and Acceptance of Digital and Sensor-Based Scenarios for Monitoring Symptoms at Home-A Qualitative-Explorative Study

Milena von Kutzleben  1 , Jan Christoph Galuska  1 , Andreas Hein  2 , Frank Griesinger  3 , Lena Ansmann  1
Affiliations

Needs of Lung Cancer Patients Receiving Immunotherapy and Acceptance of Digital and Sensor-Based Scenarios for Monitoring Symptoms at Home-A Qualitative-Explorative Study

Milena von Kutzleben et al. Int J Environ Res Public Health. .

Abstract

Background: The development of immunotherapy in the treatment for lung cancer has changed the outlook for both patients and health care practitioners. However, reporting and management of side effects are crucial to ensure effectiveness and safety of treatment. The aim of this study was to learn about the subjective experiences of patients with lung cancer receiving immunotherapy and to explore their potential acceptance of digital and sensor-based systems for monitoring treatment-related symptoms at home.

Methods: A qualitative-explorative interview study with patients with lung cancer (n = 21) applying qualitative content analysis.

Results: Participants had trouble to classify and differentiate between symptoms they experienced and it seemed challenging to assess whether symptoms are serious enough to be reported and to figure out the right time to report symptoms to health care practitioners. We identified four basic needs: (1) the need to be informed, (2) the need for a trustful relationship, (3) the need to be taken seriously, and (4) the need for needs-oriented treatment concepts. The idea of digital and sensor-based monitoring initially provoked rejection, but participants expressed more differentiated attitudes during the interviews, which could be integrated into a preliminary model to explain the acceptance of digital and sensor-based monitoring scenarios.

Conclusions: Supporting lung cancer patients and their health care providers in communicating about treatment-related symptoms is important. Technology-based monitoring systems are considered to be potentially beneficial. However, in view of the many unfulfilled information needs and the unsatisfactory reporting of symptoms, it must be critically questioned what these systems can and should compensate for, and where the limits of such monitoring lie.

Keywords: adverse events; content analysis; immunotherapy; lung cancer; palliative care; patient’s needs; preferences; qualitative research methods; side effects; technology acceptance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Digital and sensor-based scenarios for monitoring treatment-related symptoms of immunotherapy in lung cancer at home.
Figure 2
Figure 2
A preliminary model to explain the acceptance of digital and sensor-based monitoring scenarios at home among lung cancer patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pinheiro F.D., Teixeira A.F., de Brito B.B., da Silva F.A.F., Santos M.L.C., de Melo F.F. Immunotherapy—New perspective in lung cancer. World J. Clin. Oncol. 2020;11:250–259. doi: 10.5306/wjco.v11.i5.250. - DOI - PMC - PubMed
    1. Nishijima T.F., Shachar S.S., Nyrop K.A., Muss H.B. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Oncologist. 2017;22:470–479. doi: 10.1634/theoncologist.2016-0419. - DOI - PMC - PubMed
    1. Sgambato A., Casaluce F., Sacco P.C., Palazzolo G., Maione P., Rossi A., Ciardiello F., Gridelli C. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Curr. Drug Saf. 2016;11:62–68. doi: 10.2174/1574886311207040289. - DOI - PubMed
    1. Xia L., Liu Y., Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist. 2019;24:31–41. doi: 10.1634/theoncologist.2019-IO-S1-s05. - DOI - PMC - PubMed
    1. Micholt J.-M., Bigenwald C., Champiat S., Collins M., Carbonnel F., Postel-Vinay S., Berdelou A., Varga A.I., Bahleda R., Hollebecque A., et al. Immune-related adverse events with im-mune checkpoint blockade: A comprehensive review. Eur. J. Cancer. 2016;54:139–148. doi: 10.1016/j.ejca.2015.11.016. - DOI - PubMed